This comprises the eagerly anticipated summary of the second primary endpoint of the PACIFIC trial of Durvalumab vs placebo in patients who completed CT/RT without progression for unresectable stage III NSCLC. Durvalumab significantly improved overall survival, progression free survival, and time to distant metastasis or death.
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Lung - Cancer
September 21, 2018
Patient Care and General Interest
A man who received quintuple bypass surgery in Little Rock, Arkansas, USA, plans to cycle a 50-mile race only two months later.
September 20, 2018
Stephen D. Cassivi of the Mayo Clinic in Rochester, Minnesota, presents a discussion on multidisciplinary approaches to the surgical treatment of stage Illa N2 disease.
September 14, 2018
Patient Care and General Interest
3D personalized simulations of patient hearts reportedly allow physicians to better locate and treat arrhythmias.
September 6, 2018
This Thursday night, September 6, 2018, the world's biggest thoracic surgery unit is broadcasting a free live conference in English. Anyone is free to log in to see what they are doing. They will be presenting and discussing 14 different clinical cases, including lobectomy, segmentectomy, and oesophagectomy.
September 3, 2018
The authors present a transsternal transpericardial approach to perform a left main bronchus sleeve resection for a rare diagnosis of intrabronchial primitive glomus tumor.
August 31, 2018
Patient Care and General Interest
August 22, 2018
The authors present a right pneumonectomy using a biportal VATS approach for a multifocal adenocarcinoma.
August 21, 2018
For high volume surgeons (defined as 20 or more annual lobectomies), the use of a robotic approach had a lower conversion to open rate and a lower complication rate, while having a mean operating time that was 25 min longer on average compared to a VATS approach.
August 20, 2018
This provocative editorial outlines concepts that thoracic surgeons should understand in the era of immunotherapy for potentially resectable N2 disease.